Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.
Hoffmann I, Dragomir MP, Monjé N, Keunecke C, Kunze CA, Schallenberg S, Marchenko S, Schmitt WD, Kulbe H, Sehouli J, Braicu IE, Jank P, Denkert C, Darb-Esfahani S, Horst D, Sinn BV, Sers C, Bischoff P, Taube ET. Hoffmann I, et al. Among authors: jank p. Neoplasia. 2023 Oct;44:100934. doi: 10.1016/j.neo.2023.100934. Epub 2023 Sep 11. Neoplasia. 2023. PMID: 37703626 Free PMC article.
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube ET, Plett H. Sehouli J, et al. Among authors: jank p. Hum Pathol. 2019 Mar;85:299-308. doi: 10.1016/j.humpath.2018.10.020. Epub 2018 Nov 11. Hum Pathol. 2019. PMID: 30428389
MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods.
Klein O, Kanter F, Kulbe H, Jank P, Denkert C, Nebrich G, Schmitt WD, Wu Z, Kunze CA, Sehouli J, Darb-Esfahani S, Braicu I, Lellmann J, Thiele H, Taube ET. Klein O, et al. Among authors: jank p. Proteomics Clin Appl. 2019 Jan;13(1):e1700181. doi: 10.1002/prca.201700181. Epub 2018 Dec 14. Proteomics Clin Appl. 2019. PMID: 30471200
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Schneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C. Loibl S, et al. Among authors: jank p. Clin Cancer Res. 2019 Jul 1;25(13):3986-3995. doi: 10.1158/1078-0432.CCR-18-3258. Epub 2019 Apr 12. Clin Cancer Res. 2019. PMID: 30979740
What turns CREB on? And off? And why does it matter?
Steven A, Friedrich M, Jank P, Heimer N, Budczies J, Denkert C, Seliger B. Steven A, et al. Among authors: jank p. Cell Mol Life Sci. 2020 Oct;77(20):4049-4067. doi: 10.1007/s00018-020-03525-8. Epub 2020 Apr 28. Cell Mol Life Sci. 2020. PMID: 32347317 Free PMC article. Review.
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, Higgs BW, Jank P, Sinn HP, Huober J, Becker C, Blohmer JU, Marmé F, Schmitt WD, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching PA, Jackisch C, Untch M, Schneeweiss A, Loibl S. Karn T, et al. Among authors: jank p. Ann Oncol. 2020 Sep;31(9):1216-1222. doi: 10.1016/j.annonc.2020.05.015. Epub 2020 May 24. Ann Oncol. 2020. PMID: 32461104 Free article.
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, Zahm DM, Ingold-Heppner B, Schem C, Stickeler E, Fasching PA, Nekljudova V, Taube ET, Heppner F, Müller V, Denkert C, Loibl S. Jank P, et al. PLoS One. 2020 Aug 25;15(8):e0238021. doi: 10.1371/journal.pone.0238021. eCollection 2020. PLoS One. 2020. PMID: 32841306 Free PMC article.
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆.
Denkert C, Untch M, Benz S, Schneeweiss A, Weber KE, Schmatloch S, Jackisch C, Sinn HP, Golovato J, Karn T, Marmé F, Link T, Budczies J, Nekljudova V, Schmitt WD, Stickeler E, Müller V, Jank P, Parulkar R, Heinmöller E, Sanborn JZ, Schem C, Sinn BV, Soon-Shiong P, van Mackelenbergh M, Fasching PA, Rabizadeh S, Loibl S. Denkert C, et al. Among authors: jank p. Ann Oncol. 2021 Apr;32(4):500-511. doi: 10.1016/j.annonc.2020.12.016. Epub 2021 Jan 6. Ann Oncol. 2021. PMID: 33418062 Free article.
53 results